Edition:
United Kingdom

Acasti Pharma Inc (ACST.OQ)

ACST.OQ on NASDAQ Stock Exchange Capital Market

1.40USD
5:04pm GMT
Change (% chg)

$-0.10 (-6.67%)
Prev Close
$1.50
Open
$1.49
Day's High
$1.54
Day's Low
$1.40
Volume
37,491
Avg. Vol
76,331
52-wk High
$3.34
52-wk Low
$1.11

Chart for

About

Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia... (more)

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Acasti Pharma grants Chinese pharma co exclusive license to commercialize CaPre in China​

* Acasti Pharma Inc - ‍clarifies term of proposed strategic partnership with China pharmaceutical company​

22 Nov 2017

BRIEF-Acasti Pharma ‍enters into non-binding agreement with China-based pharma

* Acasti Pharma Inc - ‍entered into a non-binding term sheet with a China-based pharmaceutical company​

20 Nov 2017

BRIEF-Acasti Pharma says is offering 11.7 mln common shares‍​

* Says it is offering 11.7 million common shares‍​ - SEC Filing Source text: (http://bit.ly/2mBXlkS) Further company coverage:

16 Nov 2017

BRIEF-Acasti Pharma reports Q2 loss per share C‍$0.31​

* Acasti Pharma reports second quarter FY 2018 financial results

13 Nov 2017

BRIEF-Acasti Pharma files for offering of up to $17.25 mln of common stock‍​

* Acasti Pharma Inc files for offering of up to $17.25 million of common stock‍​ - sec filing‍​ Source text : http://bit.ly/2yN6Pf7 Further company coverage:

29 Sep 2017

BRIEF-Acasti Pharma reports Q1 loss per share c$0.19

* Acasti Pharma reports first quarter fy 2018 financial results

14 Aug 2017

BRIEF-Acasti Pharma issues common shares in payment of outstanding interest under debentures

* Acasti Pharma announces issuance of common shares in payment of outstanding interest under debentures Source text for Eikon: Further company coverage:

28 Jul 2017

Earnings vs. Estimates